ReviewMeta-analysis of psoriasis, cardiovascular disease, and associated risk factors
Section snippets
Methods
The study was conducted in accordance to Meta-analysis of Observational Studies in Epidemiology (MOOSE) recommendations.10
Literature search
We found 800 references in databases, and an additional 35 by manual screening. We excluded 760 references (Fig 1 and efile1).
A total of 75 studies including up to 503,686 cases and 29,686,694 controls covering 12 different end points were included in the meta-analyses (Fig 2, Fig 3, Fig 4, Fig 5, Fig 6). Some controls overlap if more than 1 end point from the same study is analyzed.
Cardiovascular disease
Using random effects model, psoriasis was associated with cardiovascular disease in total (odds ratio [OR] 1.4;
Discussion
To our knowledge, this study is the largest meta-analysis undertaken to study the association of psoriasis and cardiovascular diseases as well as associated risk factors with 75 studies, covering 503,686 cases and 29,686,694 controls.
In aggregate, psoriasis was associated with cardiovascular disease in total and associated risk factors, but not cerebrovascular disease and cardiovascular mortality. In subgroup analyses, hospital-based studies and insurance database studies demonstrated an
References (19)
Atherosclerosis is an inflammatory disease
Am Heart J
(1999)- et al.
Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients
Atherosclerosis
(2007) - et al.
Heart disease in psoriasis
J Am Acad Dermatol
(2007) - et al.
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis
Ann Rheum Dis
(2010) - et al.
Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database
Eur Heart J
(2010) - et al.
Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors
Semin Thromb Hemost
(2009) - et al.
Maturation of an idea: a historical perspective on the association of psoriasis with the metabolic syndrome and cardiovascular disease
Arch Dermatol
(2012) - et al.
Psoriasis and metabolic disease: epidemiology and pathophysiology
Curr Opin Rheumatol
(2008) - et al.
Cardiovascular disease and classic cardiovascular risk factors in patients with psoriasis
Int J Dermatol
(2009)
Cited by (234)
Cutaneous Sarcoidosis
2024, Clinics in Chest MedicinePsoriasis and skin cancer – Is there a link?
2023, International ImmunopharmacologyModulation of oxidative stress in psoriasis: Pathophysiology and therapy
2023, Modulation of Oxidative Stress: Biochemical, Physiological and Pharmacological AspectsAssociation between psoriasis and cardiometabolic comorbidities in a racially and ethnically diverse low-income primary care population
2024, Clinical and Experimental Dermatology
Cofinanced with grants by the Danish Agency for Science, Technology, and Innovation and LEO Pharma A/S (Dr Miller).
Disclosure: Dr Miller is cofinanced by LEO Pharma A/S. Dr Jemec reports receiving consulting fees from Abbott Laboratories, Astra-Zeneca, Coloplast, MSD, Novartis, Pfizer, and Dumex-Alpharma; lecture fees from Abbott Laboratories, Galderma, Pfizer, and Roche; grant support from Abbott Laboratories, Pfizer, Photocure, and LEO Pharma; equipment on loan from Michelson Diagnostics; and reimbursement for travel expenses from Abbott Laboratories, Galderma, and Photocure. Drs Ellervik, and Yazdanyar have no conflicts of interest to declare.